Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + SOX in first-line advanced gastric/GEJ cancer
NCT04202484Phase 2Unknown
- Sponsor
- Renji Hospital
- Start
- Feb 2020
- Primary completion
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of toripalimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Renji Hospital. Status: unknown.
02
Drugs
toripalimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04202484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04202484.